(Bloomberg) -- Eiger Biopharmaceuticals Inc., a company developing therapies for rare metabolic diseases, has filed for bankruptcy.Most Read from BloombergErdogan Suffers Historic Loss in Turkey Municipal ElectionsTrump Media Erases Debut Surge as Filings Show $58 Million LossTesla Has Wall Street Worried About How Many Cars It Just SoldGold Retreats From Record as US Factory Data Spurs Fed DebateUS Oil Suppliers Muscling Into OPEC+ Markets All Over the WorldPublicly traded Eiger listed about $3

Shares of Eiger BioPharmaceuticals plunged to an all-time low after the company filed for chapter 11 bankruptcy with a deal in hand to sell its Zokinvy drug.

Announces “Stalking Horse” Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a “stalking horse” agre

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The Company's common stock will begin trading on a post-split basi

Insiders who purchased US$3.42m worth of Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shares over the past year...

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.

Eiger BioPharmaceuticals Inc said on Tuesday it would discontinue a late-stage study testing its experimental drug to treat the most severe form of viral hepatitis, due to safety concerns. The drug candidate, peginterferon lambda, was being tested in patients with chronic hepatitis delta (CHD). "The study discontinuation is disappointing, especially for patients with chronic hepatitis delta who have limited treatment options," said Eiger CEO David Apelian.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety Monitoring Board (DSMB) for the study following its quarterly safety review. In a communication dated September 7, 2023, the

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY. Eiger will also host one-on-one meetings with investors at the conference.